Lamotrigine: Pharmacokinetics

Journal of Child Neurology

Volumn 12, Issue SUPPL. 1, 1997, Pages

  Garnett, William R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMOTRIGINE;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; EPILEPSY; FIRST PASS EFFECT; HUMAN; NONHUMAN; PRIORITY JOURNAL;

EID: 0031422928     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073897012001041     Document Type: Article

References (41)

1. Dickins M, Sawyer DA, Morley TJ, Parsons DN: Lamotrigine: Chemistry and biotransformation, in Levy RH, Mattson RH, Meldrum BS (eds): Antiepileptic Drugs, 4th ed. New York, Raven Press, 1995, pp 871-875.
2. Leach MJ, Lees G, Riddall DR: Lamotrigine: Mechanism of action, in Levy RH, Mattson RH, Meldrum BS (eds): Antiepileptic Drugs, 4th ed. New York, Raven Press, 1995, pp 861-869.
3. LAMICTAL (lamotrigine) package insert: Glaxo Wellcome Inc, Research Triangle Park, NC 27709. May 1996.
4. Parsons DN, Dickins M, Morley TJ: Lamotrigine: Absorption, distribution, and excretion, in Levy RH, Mattson RH, Meldrum BS (eds): Antiepileptic Drugs, 4th ed. New York, Raven Press, 1995, pp 877-881.
5. Yuen WC, Peck AW: Lamotrigine pharmacokinetics: oral and i.v. infusion in man. Br J Clin Pharmacol 1988;26:242.
6. Peck AW: Clinical pharmacology of lamotrigine. Epilepsia 1991; 32(Suppl 2):S9-S12.
7. Cohen AF, Land GS, Breimer DD, et al: Lamotrigine, a new anticonvulsant: Pharmacokinetics in normal humans. Clin Pharmacol Ther 1987;42:535-541.
8. Yau MK, Garnett WR, Wargin WA, Pellock JM: A single dose, dose proportionality, and bioequivalence study of lamotrigine in normal volunteers. Epilepsia 1991;32(Suppl 3):S8.
9. Ramsey RE, Pellock JM, Garnett WR, et al: Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 1991;10:191-200.
10. Mikati MA, Schacter SC, Schomer LDL, et al: Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. Clin Neuropharmacol 1989;12:312-321.
11. Richens A: Pharmacokinetics of lamotrigine, in Richens A (ed): Clinical Update on Lamotrigine: A Novel Antiepileptic Agent. Kent, Wells Medical Limited, 1992, pp 21-27.
12. Jawad S, Yuen WC, Peck AW, et al: Lamotrigine: Single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987;1:194-201.
13. Remmel RP, Sinz NW, Graves NM, Ritter FJ: Lamotrigine and lamotrigine-N-glucuronide concentrations in human blood and brain tissue. Seizure 1992;1(Suppl A):P7/34.
14. Rambeck B, Wolf P: Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993;25:433-443.
15. Yau MK, Adams MA, Wargin WA, Lai AA: A single-dose and steady-state pharmacokinetic study of lamotrigine in healthy male volunteers. Presented at the Third International Cleveland Clinic-Bethel Epilepsy Symposium, Cleveland, OH, June 16-20, 1992.
16. Magdalou J, Herber R, Bidault R, Siest G: In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. J Pharmacol Exp Ther 1992;260:1166-1173.
17. Yuen AWC: Lamotrigine: Interactions with other drugs, in Levy RH, Mattson RH, Meldrum BS (eds): Antiepileptic Drugs, 4th ed. New York, Raven Press, 1995, pp 883-887.
18. Yuen AWC, Land G, Weatherley BC, Peck AW: Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992; 33:511-513.
19. Warner T, Patsalos PN, Prevett M, et al: Lamotrigine-induced carbamazepine toxicity: An interaction with carbamazepine-10,11-epoxide. Epilepsy Res 1992;11:147-150.
20. Graves NM, Ritter FJ, Wagner ML, et al: Effect of lamotrigine on carbamazepine epoxide concentrations. Epilepsia 1991;32(Suppl 3):13.
21. Schapel GJ, Beran RG, Vajda FJE, et al: Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant partial seizures. J Neurol Neurosurg Psychiatry 1992;56:448-453.
22. Stolarek I, Blacklaw J, Thompson GG, Brodie MJ: Vigabatrin and lamotrigine: Synergism in refractory epilepsy? Epilepsia 1993; 34(Suppl 2):108-109.
23. Eriksson A-S, Hoppu K, Nergardh A, Boreus L: Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Epilepsia 1996;37:769-773.
24. Brodie MJ, Richens A, Yuen AWC for UK Lamotrigine/Carbamazepine Monotherapy Trial Group: Double blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1996;345:476-479.
25. Anderson GD, Yau MK, Gidal BE, et al: Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996;60:145-156.
26. Depot M, Powell JR, Messenheimer JA, et al: Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther 1990;48:346-355.
27. Holdich T, Whiteman P, Orme M, et al: Effect of lamotrigine on the pharmacology of the combined oral contraceptive pill. Epilepsia 1991;32(Suppl 1):96.
28. Rey E, Vauzelle F, Pons G, et al: Pharmacokinetics of lamotrigine in young epileptic children. Presented at the 5th World Conference on Clinical Pharmacology and Therapeutics, Yokohama, Japan, 1992:154.
29. Wallace SJ: Add-on open trial of lamotrigine in resistant child seizures. Brain Dev 1990;12:734.
30. Vauzelle-Kervdroedan F, Rey E, Cieuta C, et al: Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children. Br J Clin Pharmacol 1996;41:325-330.
31. Herranz JL, Arteaga R, Armijo JA: Three year efficacy and tolerability of add-on lamotrigine in treatment-resistant epileptic children. Clin Drug Invest 1996;11;214-233.
32. Glaxo Wellcome. Lamictal (Lamotrigine): Treatment of childhood epilepsies, inclulding absence seizures. Presented at the Annual Meeting of the American Epilepsy Society, December 1996.
33. Posner J, Holdich T, Crome P: Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med 1991;1:121-128.
34. Fillastre JP, Taburet AM, Fialaire A, et al: Pharmacokinetics of lamotrigine in patients with renal impairment: Influence of haemodialysis. Drugs Exp Clin Res 1993;19:25-32.
35. Burstein AH: Lamotrigine. Pharmacotherapy 1995;15:129-143.
36. Posner J, Cohen AF, Land G, et al: The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's syndrome). Br J Clin Pharmacol 1989; 28:117-120.
37. Mattson RH: Antiepileptic drug monitoring: A reppraisal. Epilepsia 1995;36(Suppl 5):S22-S29.
38. Goa KL, Ross SR, Chrisp P: Lamotrigine: A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46:152-176.
39. George S, Wood AJ, Braithwaite RA: Routine therapeutic monitoring of lamotrigine in epileptic patients using a simple and rapid high performance liquid chromatographic technique. Ann Clin Biochem 1995;32:584-588.
40. Kilpatrick ES, Forrest G, Brodie MJ: Concentration-effect and concentration-toxicity relations with lamotrigine: A prospective study. Epilepsia 1996;37:534-538.
41. Gilman JT: Lamotrigine: An antiepileptic agent for the treatment of partial seizures. Ann Pharmacol 1995;29:144-151.